Tempus Announces the Launch of Paige Predict
Following the acquisition of Paige in 2025, Tempus launches its new AI-powered, biomarker prediction solution for digital pathology
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of Paige Predict, a suite of cutting-edge digital pathology applications that analyze hematoxylin and eosin (H&E) whole slide images to help inform testing decisions. The AI-powered solution is designed to predict the likely presence or absence of clinically actionable and relevant biomarkers directly from a single H&E slide, offering physicians insights even when tissue samples are insufficient for full molecular profiling.
As the demand for next-generation sequencing (NGS) and immunohistochemistry (IHC) testing grows, so does the challenge of limited tissue availability. When a sample is "quantity not sufficient" (QNS), patients can face delays of days or weeks for testing results, waiting for repeat biopsies or alternative testing, ultimately prolonging uncertainty and potentially impacting treatment options. Paige Predict's ability to use an H&E image to identify biomarkers that are more or less likely to be present in the specimen can be used by clinicians to inform the sequence in which they will order confirmatory tissue-based tests, maximizing the likelihood of receiving an actionable result before exhausting tissue.
Leveraging Tempus and Paige's intelligent digital pathology platform and proprietary AI products, Paige Predict identifies critical biomarker information from even scarce amounts of tissue and analyzes H&E images to predict the likelihood of 123 biomarkers and oncogenic molecular pathways in 16 cancer types, including NSCLC, prostate, breast, pancreatic, colorectal, and more. Results are automatically delivered with the clinical report to ordering physicians.
Paige Predict was built using Paige's foundation model and a combined, multimodal cohort from Tempus and Paige, which contains de-identified data on over 200,000 patients. The model has been rigorously validated to demonstrate performance, generalizability and robustness across multiple, diverse datasets, including a large-scale cohort from Tempus.
"Tissue can be scarce, but insights don't have to be," said Ezra Cohen, MD, Chief Medical Officer, Oncology at Tempus. "Paige Predict overcomes one of the biggest barriers in NGS by delivering actionable information to inform critical testing decisions for patient care when sequencing isn't feasible. This is a defining moment as Tempus and Paige continue our work together following last year's acquisition, demonstrating the transformative technology our teams are bringing to digital pathology."
About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus' industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the benefits of Paige Predict in biomarker testing and clinical care. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "going to," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.
You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus' business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus' financial performance; the ability to attract and retain customers and partners; managing Tempus' growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus' intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" in Tempus' Quarterly Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission ("SEC") as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260121403553/en/
Hanah Heintzelman
[email protected]